Literature DB >> 9541571

Absence of B7.1-CD28/CTLA-4-mediated co-stimulation in human NK cells.

S Lang1, N L Vujanovic, B Wollenberg, T L Whiteside.   

Abstract

Recent studies have suggested that B7-CD28 interactions provide co-stimulatory signals for activation of NK cells. Transduction of the B7.1 (CD80) gene into tumor cells has been shown to trigger proliferation and cytotoxicity of murine NK cells and a human NK cell line, YT2C2. Therefore, transduction of the B7.1 gene into CD80-negative human squamous cell carcinomas of the head and neck (SCCHN) and its stable expression was expected to upregulate proliferation and cytotoxic activities of human NK cells. However, expression of the B7.1 receptors, CD28 and CTLA-4, could not be demonstrated on the surface or in the cytoplasm of normal human NK cells, irrespective of the state of their activation. In proliferation experiments or various cytotoxicity assays, utilizing highly purified human NK cells as responder or effector cells, no enhancement of NK cell generation or activity, respectively, by B7.1+ SCCHN was observed relative to non-transduced or LacZ gene-transduced SCCHN. In contrast, co-incubation of B7.1+ SCCHN targets with human NK cells induced significant inhibition of NK cell growth. Thus, the B7.1-CD28/CTLA-4 pathway is not involved in triggering of human adult NK cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9541571     DOI: 10.1002/(SICI)1521-4141(199803)28:03<780::AID-IMMU780>3.0.CO;2-8

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  25 in total

1.  CD28 is not directly involved in the response of human CD3- CD56+ natural killer cells to lipopolysaccharide: a role for T cells.

Authors:  M R Goodier; M Londei
Journal:  Immunology       Date:  2004-04       Impact factor: 7.397

2.  Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.

Authors:  Chihaya Imai; Shotaro Iwamoto; Dario Campana
Journal:  Blood       Date:  2005-03-08       Impact factor: 22.113

3.  Activation of human NK cells by staphylococci and lactobacilli requires cell contact-dependent costimulation by autologous monocytes.

Authors:  D Haller; P Serrant; D Granato; E J Schiffrin; S Blum
Journal:  Clin Diagn Lab Immunol       Date:  2002-05

Review 4.  NK cells and cancer: you can teach innate cells new tricks.

Authors:  Maelig G Morvan; Lewis L Lanier
Journal:  Nat Rev Cancer       Date:  2016-01       Impact factor: 60.716

Review 5.  Chimeric antigen receptor-engineered natural killer and natural killer T cells for cancer immunotherapy.

Authors:  Dominique Bollino; Tonya J Webb
Journal:  Transl Res       Date:  2017-06-09       Impact factor: 7.012

6.  PD-L1 Mediates Dysfunction in Activated PD-1+ NK Cells in Head and Neck Cancer Patients.

Authors:  Fernando Concha-Benavente; Benjamin Kansy; Jessica Moskovitz; Jennifer Moy; Uma Chandran; Robert L Ferris
Journal:  Cancer Immunol Res       Date:  2018-10-03       Impact factor: 11.151

Review 7.  Utilizing chimeric antigen receptors to direct natural killer cell activity.

Authors:  David L Hermanson; Dan S Kaufman
Journal:  Front Immunol       Date:  2015-04-28       Impact factor: 7.561

Review 8.  Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an "Off-the-Shelf Immunotherapy" for Improvement in Cancer Treatment.

Authors:  Olaf Oberschmidt; Stephan Kloess; Ulrike Koehl
Journal:  Front Immunol       Date:  2017-06-09       Impact factor: 7.561

Review 9.  Molecular checkpoints controlling natural killer cell activation and their modulation for cancer immunotherapy.

Authors:  Hyung-Joon Kwon; Nayoung Kim; Hun Sik Kim
Journal:  Exp Mol Med       Date:  2017-03-31       Impact factor: 8.718

Review 10.  CAR-engineered NK cells; a promising therapeutic option for treatment of hematological malignancies.

Authors:  Faroogh Marofi; Marwan Mahmood Saleh; Heshu Sulaiman Rahman; Wanich Suksatan; Moaed E Al-Gazally; Walid Kamal Abdelbasset; Lakshmi Thangavelu; Alexei Valerievich Yumashev; Ali Hassanzadeh; Mahboubeh Yazdanifar; Roza Motavalli; Yashwant Pathak; Adel Naimi; Behzad Baradaran; Marzieh Nikoo; Farhad Motavalli Khiavi
Journal:  Stem Cell Res Ther       Date:  2021-07-02       Impact factor: 6.832

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.